Bon Natural Life (BON) Competitors $1.39 -0.01 (-0.71%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock BON vs. PTPI, PBLA, BPTSY, SYRS, HEPA, ORGS, WINT, VIRX, TRVN, and VINCShould you be buying Bon Natural Life stock or one of its competitors? The main competitors of Bon Natural Life include Petros Pharmaceuticals (PTPI), Panbela Therapeutics (PBLA), Biophytis (BPTSY), Syros Pharmaceuticals (SYRS), Hepion Pharmaceuticals (HEPA), Orgenesis (ORGS), Windtree Therapeutics (WINT), Viracta Therapeutics (VIRX), Trevena (TRVN), and Vincerx Pharma (VINC). These companies are all part of the "pharmaceutical products" industry. Bon Natural Life vs. Its Competitors Petros Pharmaceuticals Panbela Therapeutics Biophytis Syros Pharmaceuticals Hepion Pharmaceuticals Orgenesis Windtree Therapeutics Viracta Therapeutics Trevena Vincerx Pharma Petros Pharmaceuticals (NASDAQ:PTPI) and Bon Natural Life (NASDAQ:BON) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings. Which has more risk & volatility, PTPI or BON? Petros Pharmaceuticals has a beta of 1.56, meaning that its stock price is 56% more volatile than the S&P 500. Comparatively, Bon Natural Life has a beta of -0.47, meaning that its stock price is 147% less volatile than the S&P 500. Is PTPI or BON more profitable? Bon Natural Life's return on equity of 0.00% beat Petros Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Petros PharmaceuticalsN/A -78.22% -23.50% Bon Natural Life N/A N/A N/A Which has better valuation and earnings, PTPI or BON? Bon Natural Life has higher revenue and earnings than Petros Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPetros Pharmaceuticals$5.11M0.19-$8.16M-$52.910.00Bon Natural Life$23.84M0.01$400KN/AN/A Do insiders & institutionals believe in PTPI or BON? 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.6% of Bon Natural Life shares are owned by institutional investors. 12.3% of Petros Pharmaceuticals shares are owned by insiders. Comparatively, 26.5% of Bon Natural Life shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media refer more to PTPI or BON? In the previous week, Petros Pharmaceuticals' average media sentiment score of 0.00 equaled Bon Natural Life'saverage media sentiment score. Company Overall Sentiment Petros Pharmaceuticals Neutral Bon Natural Life Neutral SummaryBon Natural Life beats Petros Pharmaceuticals on 5 of the 8 factors compared between the two stocks. Get Bon Natural Life News Delivered to You Automatically Sign up to receive the latest news and ratings for BON and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BON vs. The Competition Export to ExcelMetricBon Natural LifeCONSM PD IndustryDiscretionary SectorNASDAQ ExchangeMarket Cap$232K$2.37B$8.41B$9.77BDividend YieldN/A4.51%3.04%4.08%P/E RatioN/A17.1017.8626.04Price / Sales0.012.385.33104.72Price / Cash0.1316.3915.0628.79Price / Book0.001.674.956.08Net Income$400K$106.49M$226.41M$265.64M7 Day Performance2.96%-0.02%14.94%3.11%1 Month Performance0.72%-9.60%12.80%0.39%1 Year PerformanceN/A-18.47%45.63%18.52% Bon Natural Life Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BONBon Natural LifeN/A$1.39-0.7%N/AN/A$232K$23.84M0.00100Gap DownPTPIPetros PharmaceuticalsN/A$0.03-1.8%N/A-99.6%$857K$5.11M-0.0120PBLAPanbela Therapeutics0.3173 of 5 stars$0.16flatN/A-54.2%$767KN/A0.006BPTSYBiophytisN/A$2.00flatN/A-70.0%$702KN/A0.0030SYRSSyros Pharmaceuticals4.0544 of 5 stars$0.02+1,143.8%$1.00+4,925.1%-99.9%$534K$386K-0.01120Positive NewsHEPAHepion Pharmaceuticals0.5539 of 5 stars$0.05-4.5%N/A-99.8%$491KN/A-0.0120ORGSOrgenesis1.6443 of 5 stars$0.10-90.0%N/AN/A$480K$662K0.00150News CoverageGap DownWINTWindtree Therapeutics2.5309 of 5 stars$0.13-5.1%$350.00+269,130.8%-100.0%$476KN/A0.0030Earnings ReportGap UpVIRXViracta Therapeutics1.7127 of 5 stars$0.01flat$1.13+11,403.1%N/A$389KN/A-0.0120TRVNTrevena1.2871 of 5 stars$0.28flat$5.00+1,718.2%-93.5%$264K$443K-0.0140VINCVincerx Pharma2.5407 of 5 stars$0.04+4.5%$40.00+101,422.8%-99.7%$197KN/A0.0060Gap Down Related Companies and Tools Related Companies Petros Pharmaceuticals Competitors Panbela Therapeutics Competitors Biophytis Competitors Syros Pharmaceuticals Competitors Hepion Pharmaceuticals Competitors Orgenesis Competitors Windtree Therapeutics Competitors Viracta Therapeutics Competitors Trevena Competitors Vincerx Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BON) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bon Natural Life Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Bon Natural Life With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access